EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group

Alberto Carmona-Bayonas, Axel Mariño Méndez, María Ángeles Vicente-Conesa, Paula Jimenez-Fonseca, María de Toro Carmena, Carmen Guillen-Ponce, Angela Lamarca, Mónica Benavente, Javier Gallego, Paula Cerdà Serdà, Raquel Hernández San Gil, Kreina Sharela Vega-Cano und 9 weitere

Pancreatology · 2026-11 · 26 (7) · 995-1004

DOI: 10.1016/j.pan.2026.08.008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pancreatology, 2026-11. Verfasst von Alberto Carmona-Bayonas und 20 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Inflammation, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Spanish Society of Medical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Systemic inflammation is a key driver of progression in pancreatic ductal adenocarcinoma (PDAC). We aimed to externally validate the Systemic Inflammation Response Index (SIRI) and define its non-linear prognostic value in a large multicenter cohort. METHODS: We analyzed 672 patients with metastatic PDAC receiving first-line chemotherapy across 30 centers. SIRI was assessed using a validated cut-off (>2.3) and as a log-transformed continuous variable in multivariable Weibull accelerated failure-time models with restricted cubic splines. RESULTS: Patients with low SIRI (≤2.3) had longer median OS (14.0 vs 9.2 months; p < 0.001) and PFS (5.9 vs 3.9 months; p < 0.001) than those with high SIRI. High SIRI was associated with a lower objective response rate (25% vs 37%; p < 0.001). In multivariable analyses, higher SIRI independently predicted inferior OS and PFS (75th vs 25th percentile: HR 1.14 [95% CI 1.05-1.25], HR 1.11 [95% CI 1.03-1.21]) and poorer tumor response (OR 0.78; 95% CI 0.62-1.00). Higher SIRI correlated with greater hepatic tumor burden and cachexia. CONCLUSIONS: SIRI is a robust, independent prognostic marker in metastatic PDAC. Higher values identify a phenotype with inferior survival and poorer tumor response. An open-access web calculator is provided to illustrate and explore the nonlinear, continuous prognostic gradient of SIRI and its impact on outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalInflammationAntineoplastic AgentsHumansFemaleMaleAgedMiddle AgedPrognosisTreatment OutcomeNeoplasm MetastasisCohort Studies

Stichwörter der Autor:innen

BiomarkerPancreatic cancerPrecision oncologySIRISystemic inflammation

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
  • Medical Oncology Department, Hospital Universitario Central de Asturias, Universidad de Oviedo, ISPA, Oviedo, Spain.
  • Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain.
  • Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.
  • Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Medical Oncology Department, Fundación Jiménez Díaz University Hospital - Health Research Institute Fundación Jiménez Díaz (IIS-FJD) - Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Förderung

  • Spanish Society of Medical Oncology

Zitieren

APA

Carmona-Bayonas, A., Mariño Méndez, A., Vicente-Conesa, M. Á., Jimenez-Fonseca, P., de Toro Carmena, M., Guillen-Ponce, C., Lamarca, A., Benavente, M., Gallego, J., Cerdà Serdà, P., Hernández San Gil, R., Vega-Cano, K. S., López, A., Soriano Tabares de Navas, M. L., Peirò, I., Parra-Paladines, W., Zwisler-Contreras, P., Brozos-Vázquez, E., Cabezon-Gutiérrez, L., …, & Pacheco-Barcia, V. (2026). Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group. Pancreatology, 26(7), 995-1004. https://doi.org/10.1016/j.pan.2026.08.008

Vancouver

Carmona-Bayonas A, Mariño Méndez A, Vicente-Conesa MÁ, Jimenez-Fonseca P, de Toro Carmena M, Guillen-Ponce C, et al. Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group. Pancreatology. 2026;26(7):995-1004. doi:10.1016/j.pan.2026.08.008

BibTeX
@article{CarmonaBayonas2026,
  author = {Carmona-Bayonas, Alberto and Mariño Méndez, Axel and Vicente-Conesa, María Ángeles and Jimenez-Fonseca, Paula and de Toro Carmena, María and Guillen-Ponce, Carmen and Lamarca, Angela and Benavente, Mónica and Gallego, Javier and Cerdà Serdà, Paula and Hernández San Gil, Raquel and Vega-Cano, Kreina Sharela and López, Ana and Soriano Tabares de Navas, Maria Luisa and Peirò, Inmaculada and Parra-Paladines, Wagner and Zwisler-Contreras, Patricia and Brozos-Vázquez, Elena and Cabezon-Gutiérrez, Luis and Muñoz Martin, Andrés and Pacheco-Barcia, Vilma},
  title = {Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group},
  journal = {Pancreatology},
  year = {2026},
  volume = {26},
  number = {7},
  pages = {995--1004},
  doi = {10.1016/j.pan.2026.08.008}
}
Kostenlos starten →